Product image of Menopur (Menotrophin) supplied by GNH India

Menopur

Active Ingredient:
Menotrophin
Origin:
EU

Menopur (Menotrophin)

Menotrophin, the active ingredient in Menopur, is a human menopausal gonadotropin (hMG) presented as a sterile aqueous solution for subcutaneous injection. It is used in assisted reproductive technology to stimulate ovarian follicular development and induce ovulation in women with anovulation or oligo‑ovulation.

GNH India supplies Menopur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, fertility clinics, and pharmacies worldwide, ensuring consistent quality and regulatory compliance.

Manufacturer / TM Owner

Ferring Hellas Mepe

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Menopur (menotrophin) acts on the hypothalamic‑pituitary‑gonadal axis to support ovarian stimulation in infertility treatment.

  • Induction of ovulation in women with anovulation or oligo‑ovulation: promotes follicular growth and triggers ovulation.
  • Controlled ovarian hyperstimulation for in‑vitro fertilisation (IVF): provides FSH and LH activity to develop multiple mature follicles.
  • Assisted reproductive techniques such as intracytoplasmic sperm injection (ICSI): enhances oocyte yield for laboratory fertilisation procedures.

How It Works

  • Menotrophin contains both follicle‑stimulating hormone (FSH) and luteinizing hormone (LH) isoforms that bind to their respective receptors on ovarian granulosa and theca cells. Activation of FSH receptors stimulates follicular recruitment and estrogen production, while LH receptor activation supports theca cell androgen synthesis and final follicular maturation, together facilitating ovulation. The combined activity mimics the natural gonadotropin surge, allowing controlled ovarian stimulation in assisted reproduction cycles.

Side Effects

Menopur may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

  • Injection site pain: mild discomfort or erythema at the injection site.
  • Abdominal bloating: transient abdominal distension or discomfort.
  • Headache: mild to moderate headache.
  • Nausea: occasional nausea without vomiting.

Serious or Rare Side Effects

  • Ovarian hyperstimulation syndrome (OHSS): severe fluid shift and ovarian enlargement.
  • Multiple pregnancy: increased risk of twins or higher‑order gestations.
  • Thromboembolic events: rare blood clot formation.

Precautions & Warnings

Before initiating Menopur therapy, clinicians should consider several precautionary measures to minimize risks.

  • Assess ovarian reserve: evaluate baseline follicle count and hormone levels.
  • Monitor estradiol levels: regular serum estradiol testing during stimulation.
  • Ultrasound surveillance: perform serial transvaginal ultrasounds to track follicle growth.
  • Adjust dose in high responders: reduce dosage if rapid follicular response observed.
  • Contraindications: avoid use in pregnancy, uncontrolled thyroid disease, or active ovarian cysts.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Menopur can interact with other medications or hormonal agents, influencing its efficacy or safety.

Major Interactions (Avoid)

  • GnRH agonists/antagonists: concurrent use may alter gonadotropin response.
  • Oral contraceptives: must be discontinued before stimulation to avoid suppression.
  • Dopamine agonists (e.g., bromocriptine): may reduce prolactin‑mediated effects.

Moderate Interactions (Monitor Closely)

  • Thyroid hormone replacement: monitor thyroid function as gonadotropins can affect hormone balance.
  • Anticoagulants: OHSS risk may increase bleeding tendency.
  • Steroids: may affect ovarian response; adjust monitoring.

Frequently Asked Questions

Menopur is used in infertility treatment to stimulate the ovaries. It induces ovulation in women who do not ovulate regularly and supports controlled ovarian hyperstimulation for procedures such as in‑vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI).

Menotrophin contains both follicle‑stimulating hormone (FSH) and luteinizing hormone (LH). These hormones bind to receptors on ovarian cells, promoting follicle growth, estrogen production, and final maturation of the oocyte, thereby mimicking the natural hormonal surge that leads to ovulation.

The dose of Menopur is individualized. A qualified prescriber determines the amount, frequency, and duration of treatment based on the patient’s ovarian reserve, response to monitoring, and the specific assisted‑reproductive protocol being used.

Menopur is not intended for use during an established pregnancy, and its safety in breastfeeding has not been established. It is generally avoided in these situations, and treatment is stopped once pregnancy is confirmed.

To order Menopur, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Menopur is a urinary‑derived human menopausal gonadotropin that provides both FSH and LH activity in a single preparation. Recombinant products often contain only FSH, requiring a separate LH source if needed. Menopur’s combined activity can simplify dosing but may have slightly higher batch‑to‑batch variability compared with fully recombinant formulations.

Menopur should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Keep it in the original packaging until use to maintain stability and sterility.

Menopur is given by subcutaneous injection, usually into the abdomen or thigh. The injection is performed by a trained healthcare professional or by the patient after appropriate instruction, following aseptic technique.

The most serious risks include ovarian hyperstimulation syndrome (OHSS), which can cause severe abdominal pain and fluid shifts, multiple pregnancy, and rare thromboembolic events. Prompt medical evaluation is required if any of these symptoms develop.

Menopur should not be used in women who are already pregnant, have uncontrolled thyroid disease, active ovarian cysts, severe ovarian failure, or known hypersensitivity to any component of the product. It is also contraindicated in patients with certain hormonal cancers.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.